IMAB

I-Mab [IMAB] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

IMAB Stock Summary

Earnings are expected to fall -100% next year

EPS has been decreasing for the past 3 years (Yearly statements)

IMAB has less than 1 year of cash runway

In the News

IMAB Financial details

Company Rating

Neutral

Market Cap

150.21M

Income

-5.17B

Revenue

-3.27B

Book val./share

29.41

Cash/share

35.41

Dividend

Dividend %

Employees

378

Optionable

Shortable

Yes

Earnings

14 Mar 2024

P/E

-0.51

Forward P/E

PEG

-0.04

P/S

-5.94

P/B

0.41

P/C

0.05

P/FCF

-1.15

Quick Ratio

5.35

Current Ratio

5.5

Debt / Equity

0.03

LT Debt / Equity

0.01

EPS (TTM)

-67.82

EPS next Y

EPS next Q

EPS this Y

3.45%

EPS next Y

EPS next 5Y

EPS last 5Y

28.53%

Revenue last 5Y

NAN%

Revenue Q/Q

-100.16%

EPS Q/Q

-96.58%

SMA20

SMA50

SMA100

Inst Own

23.7%

Inst Trans

0.96%

ROA

-59%

ROE

-64%

ROC

-0.55%

Gross Margin

112%

Oper. Margin

846%

Profit Margin

1089%

Payout

Shs Outstand

Shs Float

Target Price

52W Range

1.16-3.76

52W High

-40%

52W Low

+80%

RSI

Rel Volume

0.75

Avg Volume

407.49K

Volume

307.47K

Perf Week

-0.55%

Perf Month

-2.7%

Perf Quarter

47.54%

Perf Half Y

29.5%

Beta

1.108

Volatility

0.01%, 0.03%

Prev Close

Price

1.8

Change

IMAB Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	1.21	0.52	22.6	1.16	-2.92
Net income per share	-9.05	-25.16	6.9	-30.69	-31.75
Operating cash flow per share	-6.3	-15.01	6.35	-12.81	-14.52
Free cash flow per share	-6.63	-15.22	6.24	-13.2	-15.12
Cash per share	41.42	20.22	70.19	56.3	45.41
Book value per share	-21.45	-35.18	82.45	60.4	39.6
Tangible book value per share	-28.45	-40.57	78.3	56.68	35.9
Share holders equity per share	-21.45	-35.18	82.45	60.4	39.6
Interest debt per share	3.56	2.34	0.21	1.44	0.99
Market cap	3.83B	5.03B	21B	22.94B	2.19B
Enterprise value	2.39B	4.03B	16.25B	19.53B	-949.24M
P/E ratio	-9.5	-3.46	44.59	-9.84	-0.91
Price to sales ratio	71.15	167.68	13.61	260.58	-9.88
POCF ratio	-13.63	-5.8	48.44	-23.57	-1.99
PFCF ratio	-12.97	-5.71	49.35	-22.87	-1.91
P/B Ratio	-4.01	-2.47	3.73	5	0.73
PTB ratio	-4.01	-2.47	3.73	5	0.73
EV to sales	44.35	134.18	10.54	221.83	4.28
Enterprise value over EBITDA	-6.23	-2.84	33.58	-8.36	0.39
EV to operating cash flow	-8.5	-4.64	37.49	-20.07	0.86
EV to free cash flow	-8.08	-4.57	38.2	-19.47	0.83
Earnings yield	-0.11	-0.29	0.02	-0.1	-1.1
Free cash flow yield	-0.08	-0.17	0.02	-0.04	-0.52
Debt to equity	-0.15	-0.07	0	0.02	0.02
Debt to assets	0.06	0.08	0	0.02	0.02
Net debt to EBITDA	3.77	0.71	-9.8	1.46	1.3
Current ratio	5.88	2.31	9.28	7.66	5.5
Interest coverage	-37.51	-489.79	481.68	692.51	-208.22K
Income quality	0.7	0.6	0.92	0.42	0.44
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0.02	0	0
Sales general and administrative to revenue	1.23	21.82	0.26	10.22	-3.25
Research and developement to revenue	7.92	28.01	0.64	13.78	-4.08
Intangibles to total assets	0.13	0.18	0.04	0.05	0.07
Capex to operating cash flow	0.05	0.01	-0.02	0.03	0.04
Capex to revenue	-0.27	-0.41	-0.01	-0.34	0.21
Capex to depreciation	-2.14	-0.78	-0.35	-0.88	-0.72
Stock based compensation to revenue	0.07	12.23	0.32	6.91	-1.61
Graham number	66.08	141.12	113.14	204.24	168.21
ROIC	0.55	0.78	0.08	-0.43	-0.6
Return on tangible assets	-0.2	-1.02	0.08	-0.44	-0.64
Graham Net	-32.99	-44.77	62.82	47.49	31.65
Working capital	1.69B	772.84M	4.77B	4.16B	2.97B
Tangible asset value	-1.27B	-2.35B	5.34B	4.31B	2.73B
Net current asset value	-1.29B	-2.41B	4.64B	3.74B	2.56B
Invested capital	-0.15	-0.07	0	0.02	0.02
Average receivables	14M	39.89M	304.61M	515.52M	278.98M
Average payables	41.09M	31.88M	-1.96M	-1.18M	-1.18M
Average inventory	0	-27.94M	-239.36M	-197.81M	-26.52M
Days sales outstanding	162.24	679.75	130.93	1.98K	-132.25
Days payables outstanding	0	0	0	-18.62	0
Days of inventory on hand	0	0	0	214.11	-1.08K
Receivables turnover	2.25	0.54	2.79	0.18	-2.76
Payables turnover	0	0	0	-19.6	0
Inventory turnover	0	0	0	1.7	-0.34
ROE	0.42	0.72	0.08	-0.51	-0.8
Capex per share	-0.32	-0.21	-0.12	-0.39	-0.6

Quarterly Fundamentals Overview

Last date of statement is 2023-06-30 for Q2

Metric	2022-06-30	2022-09-30	2022-12-31	2023-05-01	2023-06-30
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	0.1	0	-23.23	0	0.03
Net income per share	-1.97	0	-39.2	0	-1.34
Operating cash flow per share	-1.04	0	-27.9	0	0
Free cash flow per share	-1.08	0	-28.4	0	0
Cash per share	47.77	0	45.41	0	35.41
Book value per share	48.91	0	39.6	0	29.41
Tangible book value per share	45.48	0	35.9	0	26.03
Share holders equity per share	48.91	0	39.6	0	29.41
Interest debt per share	1.26	0	0.75	0	0.93
Market cap	6.22B	0	2.19B	0	1.8B
Enterprise value	2.61B	-3.21B	-949.24M	-2.36B	-478.16M
P/E ratio	-9.62	0	-0.18	0	-4.04
Price to sales ratio	776.91	0	-1.24	0	636.06
POCF ratio	-72.75	0	-1.03	0	0
PFCF ratio	-70.35	0	-1.02	0	0
P/B Ratio	1.55	0	0.73	0	0.74
PTB ratio	1.55	0	0.73	0	0.74
EV to sales	326.13	0	0.54	0	-168.62
Enterprise value over EBITDA	-20.93	0	0.31	0	4.53
EV to operating cash flow	-30.54	0	0.45	0	0
EV to free cash flow	-29.53	0	0.44	0	0
Earnings yield	-0.03	0	-1.36	0	-0.06
Free cash flow yield	-0.01	0	-0.99	0	0
Debt to equity	0.03	0	0.02	0	0.03
Debt to assets	0.02	0	0.02	0	0.02
Net debt to EBITDA	28.94	0	1.04	0	21.62
Current ratio	7.31	5.5	5.5	4.64	4.64
Interest coverage	0	0	167.03	0	-3.07K
Income quality	0.53	0	0.71	0	0
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	0	0	-0.23	0	0
Research and developement to revenue	8.73	0	-0.05	0	22.71
Intangibles to total assets	0.06	0.07	0.07	0.08	0.08
Capex to operating cash flow	0.03	0	0.02	0	0
Capex to revenue	-0.36	0	0.02	0	0
Capex to depreciation	-1.5	0	-3.13	0	0
Stock based compensation to revenue	0	0	-0.15	0	0
Graham number	46.53	0	186.9	0	29.78
ROIC	-0.04	0	-0.95	0	-0.04
Return on tangible assets	-0.03	0	-0.79	0	-0.03
Graham Net	38.6	0	31.65	0	22.91
Working capital	3.72B	2.97B	2.97B	2.41B	2.41B
Tangible asset value	3.73B	2.73B	2.73B	2.17B	2.17B
Net current asset value	3.34B	2.56B	2.56B	2.01B	2.01B
Invested capital	0.03	0	0.02	0	0.03
Average receivables	0	154.09M	40.14M	40.14M	51.17M
Average payables	0	0	0	0	0
Average inventory	0	-8.3M	-40.14M	-40.14M	-51.17M
Days sales outstanding	3.47K	0	-4.1	0	3.25K
Days payables outstanding	0	0	0	0	0
Days of inventory on hand	-243.02	0	-265.26	0	0
Receivables turnover	0.03	0	-21.98	0	0.03
Payables turnover	0	0	0	0	0
Inventory turnover	-0.37	0	-0.34	0	0
ROE	-0.04	0	-0.99	0	-0.05
Capex per share	-0.04	0	-0.5	0	0

IMAB Frequently Asked Questions

What is I-Mab stock symbol ?

I-Mab is a CN stock and trading under the symbol IMAB

What is I-Mab stock quote today ?

I-Mab stock price is $1.8 today.

Is I-Mab stock public?

Yes, I-Mab is a publicly traded company.

Something similar

Top by Market Cap

Same Sector

Same Price Range

Similar Market Cap

Company Profile

Volume Average 407.49K
Market Capitalization 150.21M
Employee 378
CEO Mr. Raj Kannan
Headquarters Shanghai,CN
IPO Date 2020-01-17
Website https://www.i-mabbiopharma.com

I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinical trials to treat pediatric growth hormone deficiency; TJ107, a recombinant human IL-7, which is in Phase 2 for cancer treatment-related lymphopenia and cancer immunotherapy; and Lemzoparlimab, a CD47 monoclonal antibody that has completed Phase 2 clinical trial. Its product candidates also includes Enoblituzumab, a humanized B7-H3 antibody that is in Phase 2 to treat head and neck cancer, and other oncology diseases; Efineptakin, a long-acting recombinant human IL-7, which is in Phase 2 clinical trials to treat lymphopenia and cancer immunotherapy; TJ210, a monoclonal antibody against human C5aR1 that is in Phase 1 for the treatment of cancers and autoimmune; Plonmarlimab, a GM-CSF monoclonal antibody for inflammation and CRS-related therapies; Uliledlimab, a CD73 antibody, which is in Phase 2 clinical trials for treating solid tumors and oncology; TJ-L14B, a PD-L1-based tumor-dependent T-cell engager for solid cancers; and TJ-CD4B, a tumor-dependent T cell engager for gastric and other cancers, as well as TJ-L1IF, a PD-L1/IFN-a antibody-cytokine fusion protein for solid tumors and TJ-C64B, a tumor-dependent T-cell engager for ovarian and other cancers. I-Mab has strategic collaboration agreement with AbbVie Ireland Unlimited Company; Sinopharm Group Co. Ltd.; PT Kalbe Genexine Biologics; and Roche Diagnostics. The company was founded in 2014 and is headquartered in Shanghai, the People's Republic of China.